PSEN2-Mutant Neurons

PSEN2-Mutant Neurons

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">PSEN2-Mutant Neurons</th>
</tr>
<tr> [@matsuzaki2018]
<td class="infobox-label">Mutation Type</td> [@cuetolachos2013]
<td>Familial Alzheimer's Disease</td> [@zhang2016]
</tr> [@brunner2014]
<tr>
<td class="infobox-label">Gene Affected</td>
<td>PSEN2 (Presenilin-2)</td>
</tr>
<tr>
<td class="infobox-label">Common Mutations</td>
<td>N141I, M239V, A85V, R62H</td>
</tr>
<tr>
<td class="infobox-label">Inheritance</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td class="infobox-label">Disease</td>
<td>[Familial Alzheimer's Disease](/diseases/alzheimers-disease)</td>
</tr>
</table>

PSEN2-Mutant Neurons

Overview

Psen2 Mutant [Neurons](/entities/neurons) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

PSEN2-mutant neurons carry pathogenic mutations in the Presenilin-2 gene (PSEN2), which encodes [presenilin-2](/entities/psen2), a homolog of [presenilin-1](/entities/psen1) and another catalytic subunit of the [gamma-secretase](/entities/gamma-secretase) complex. While PSEN2 mutations are less common than PSEN1 mutations, they cause familial [Alzheimer's disease](/diseases/alzheimers-disease) (FAD) with typically later onset (mean age 55-65 years) and more variable disease progression compared to PSEN1.

PSEN2-Mutant Neurons

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">PSEN2-Mutant Neurons</th>
</tr>
<tr> [@matsuzaki2018]
<td class="infobox-label">Mutation Type</td> [@cuetolachos2013]
<td>Familial Alzheimer's Disease</td> [@zhang2016]
</tr> [@brunner2014]
<tr>
<td class="infobox-label">Gene Affected</td>
<td>PSEN2 (Presenilin-2)</td>
</tr>
<tr>
<td class="infobox-label">Common Mutations</td>
<td>N141I, M239V, A85V, R62H</td>
</tr>
<tr>
<td class="infobox-label">Inheritance</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td class="infobox-label">Disease</td>
<td>[Familial Alzheimer's Disease](/diseases/alzheimers-disease)</td>
</tr>
</table>

PSEN2-Mutant Neurons

Overview

Psen2 Mutant [Neurons](/entities/neurons) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

PSEN2-mutant neurons carry pathogenic mutations in the Presenilin-2 gene (PSEN2), which encodes [presenilin-2](/entities/psen2), a homolog of [presenilin-1](/entities/psen1) and another catalytic subunit of the [gamma-secretase](/entities/gamma-secretase) complex. While PSEN2 mutations are less common than PSEN1 mutations, they cause familial [Alzheimer's disease](/diseases/alzheimers-disease) (FAD) with typically later onset (mean age 55-65 years) and more variable disease progression compared to PSEN1.

Molecular Mechanisms

Gamma-Secretase Activity

Presenilin-2 functions similarly to presenilin-1 as the proteolytic core of gamma-secretase:

• Altered [APP](/entities/app-protein) processing: PSEN2 mutations shift [Aβ](/proteins/amyloid-beta) production toward longer, more aggregation-prone species
• Reduced proteolytic efficiency: Some mutations decrease overall gamma-secretase activity
• Aβ42 elevation: Most PSEN2 mutations increase Aβ42 production

Distinct Pathogenic Pathways

PSEN2 has some unique functions beyond gamma-secretase:

• Calcium regulation: PSEN2 affects ER calcium stores differently than PSEN1
• [Apoptosis](/entities/apoptosis) regulation: Distinct effects on apoptotic pathways
• Protein folding: Involvement in ER stress responses
• Mitochondrial function: Different mitochondrial effects compared to PSEN1

Cellular Phenotypes

In Vitro Characteristics

PSEN2-mutant neurons show:

• Elevated Aβ42/40 ratio (typically 1.5-3x increase)
• Altered calcium signaling
• Increased sensitivity to apoptotic stimuli
• Synaptic dysfunction
• Mitochondrial abnormalities

Comparison with PSEN1

| Feature | PSEN2-Mutant | PSEN1-Mutant |
|---------|-------------|--------------|
| Aβ42 increase | Moderate (1.5-3x) | Higher (2-10x) |
| Onset age | Later (~60 years) | Earlier (~45 years) |
| Phenotypic variability | Greater | More consistent |
| Calcium dysregulation | Different pattern | Similar pattern |

Brain Region Distribution

PSEN2-related pathology affects:

• [Hippocampus](/brain-regions/hippocampus): Especially CA1 and subiculum
• [Cortex](/brain-regions/cortex): Frontal and temporal cortices
• Amygdala: Early involvement
• Thalamus: Variable involvement

Therapeutic Considerations

Treatment Approaches

Biomarkers

PSEN2 carriers show:

• Variable CSF Aβ42 levels
• Later positive amyloid PET
• Slower disease progression than PSEN1 carriers

Model Systems

• Patient-derived iPSC neurons
• PSEN2 N141I knock-in mice
• PSEN2-deficient mouse models

Overview

Psen2 Mutant Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Psen2 Mutant Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [Alzheimer's Disease Genetics Consortium](https://www.niagads.org/)
• [Human PSEN2 Gene Database](https://www.alzgene.org/gene/PSEN2)